text
"['\n1. 요약재무정보\n당사는 2018년 9월 19일 발표된 [제약ㆍ바이오 기업의 연구개발비 회계처리 관련 감독지침]을 고려, 개발비 자산화 시점의 회계처리 오류(무형자산 과대계상 및 경상연구개발비 과소계상 등)를 수정하였으며, 이에 따라 제27기(전기) 및 제26기(전전기) 재무재표는 소급 재작성되었습니다. \n가. 요약연결재무정보\n(단위: 원)\n구 분\n제28기\n제27기\n제26기\n(2018년 12월말)\n(2017년 12월말)\n(2016년 12월말)\n[유동자산]\n1,664,478,918,682 \n1,614,033,788,024 \n1,253,249,662,127 \n ㆍ현금및현금성자산\n410,547,608,852 \n419,205,662,651 \n268,408,116,475 \n ㆍ단기금융자산\n121,636,304,845 \n138,717,014,000 \n5,765,335,000 \n ㆍ매출채권\n807,711,314,915 \n828,394,032,126 \n758,305,090,542 \n ㆍ기타수취채권\n124,267,624,254 \n3,211,880,582 \n4,830,010,171 \n ㆍ재고자산\n163,114,412,936 \n199,481,840,555 \n183,938,986,135 \n ㆍ당기법인세자산\n9,523,563,778 \n9,780,837,220 \n9,903,568,960 \n ㆍ기타유동자산\n27,678,089,102 \n15,242,520,890 \n22,098,554,844 \n[비유동자산]\n1,876,147,755,272\n1,701,493,916,629 \n1,643,597,744,102 \n ㆍ장기금융자산\n18,989,084,041 \n15,686,919,883 \n15,342,266,303 \n ㆍ장기매출채권\n0 \n0 \n517,859,475 \n ㆍ장기기타수취채권\n10,287,886,409 \n8,562,470,441 \n8,502,191,390 \n ㆍ관계기업투자\n28,003,078,925 \n17,006,445,302 \n6,157,106,430 \n ㆍ유형자산\n881,437,749,875 \n844,212,382,151 \n867,921,681,510 \n ㆍ무형자산\n922,339,536,489 \n809,790,408,679 \n720,181,970,037 \n ㆍ이연법인세자산\n0 \n0 \n20,640,513,438 \n ㆍ기타비유동자산\n15,090,419,533 \n6,235,290,173 \n4,334,155,519 \n자산총계\n3,540,626,673,954 \n3,315,527,704,653 \n2,896,847,406,229 \n[유동부채]\n678,087,471,395 \n616,781,029,714 \n610,253,362,180 \n[비유동부채]\n229,761,340,951 \n266,817,280,825 \n212,720,844,392 \n부채총계\n907,848,812,346 \n883,598,310,539 \n822,974,206,572 \n[자본금]\n125,456,133,000 \n122,666,424,000 \n116,598,327,000 \n[주식발행초과금]\n761,047,500,208 \n741,748,885,673 \n729,423,471,164 \n[이익잉여금]\n1,701,825,879,780 \n1,449,703,520,884 \n1,073,064,705,196 \n[기타포괄손익누계액]\n9,970,124,880 \n8,720,587,567 \n6,513,014,001 \n[기타자본항목]\n(74,277,317,105)\n(13,947,041,218)\n29,166,096,268 \n[비지배지분]\n108,755,540,845 \n123,037,017,208 \n119,107,586,028 \n자본총계\n2,632,777,861,608 \n2,431,929,394,114 \n2,073,873,199,657 \n(2018.01.01~2018.12.31)\n(2017.01.01~2017.1.31)\n(2016.01.01~2016.1.31)\n매출액\n982,074,959,799 \n949,079,965,214 \n670,580,961,669 \n영업이익\n338,694,787,468 \n507,828,939,197 \n234,243,034,062\n법인세비용차감전순이익\n317,725,828,715 \n491,503,197,927 \n210,433,293,219 \n당기순이익\n253,563,110,762 \n386,156,799,413 \n162,418,660,913 \n ㆍ지배기업소유주지분\n261,841,768,570 \n382,467,031,688 \n165,262,391,182 \n ㆍ비지배지분\n(8,278,657,808)\n3,689,767,725 \n(2,843,730,269)\n ㆍ기본주당이익\n2,100 \n3,070 \n1,330 \n연결에 포함된 회사수\n8\n6\n7\n나. 요약재무정보\n(단위: 원)\n구 분\n제28기\n제27기\n제26기\n(2018년 12월말)\n(2017년 12월말)\n(2016년 12월말)\n[유동자산]\n1,482,507,600,161 \n1,421,211,524,496 \n1,076,603,083,554 \n ㆍ현금및현금성자산\n399,558,425,745 \n413,501,866,488 \n257,604,838,606 \n ㆍ단기금융자산\n121,636,304,845 \n138,402,014,000 \n5,450,335,000 \n ㆍ매출채권\n689,472,264,429 \n713,489,012,682 \n678,463,204,095 \n ㆍ기타수취채권\n123,885,214,981 \n3,133,116,830 \n3,864,647,697 \n ㆍ재고자산\n125,915,033,826 \n141,164,307,648 \n113,118,543,355 \n ㆍ기타유동자산\n22,040,356,335 \n11,521,206,848 \n18,101,514,801 \n[비유동자산]\n1,925,650,130,627 \n1,738,404,699,064 \n1,646,143,636,158 \n ㆍ장기금융자산\n17,407,490,899 \n14,354,326,741 \n14,009,673,161 \n ㆍ장기기타수취채권\n9,141,484,165 \n7,169,744,638 \n7,053,707,465 \n ㆍ종속기업및관계기업투자\n286,212,166,532 \n273,099,081,283 \n262,117,281,283 \n ㆍ유형자산\n677,870,722,592 \n635,989,041,524 \n649,440,392,764 \n ㆍ무형자산\n914,462,126,420 \n795,910,154,122 \n703,792,726,623 \n ㆍ투자부동산\n5,982,493,446 \n6,147,170,166 \n6,336,536,303 \n ㆍ기타비유동자산\n14,573,646,573 \n5,735,180,590 \n3,393,318,559 \n자산총계\n3,408,157,730,788 \n3,159,616,223,560 \n2,722,746,719,712 \n[유동부채]\n548,121,290,075 \n491,067,961,229 \n524,271,608,642 \n[비유동부채]\n218,455,704,094 \n242,174,301,750 \n125,584,949,957 \n부채총계\n766,576,994,169 \n733,242,262,979 \n649,856,558,599 \n[자본금]\n125,456,133,000 \n122,666,424,000 \n116,598,327,000 \n[주식발행초과금]\n761,047,500,208 \n741,748,885,673 \n729,423,471,164 \n[이익잉여금]\n1,830,849,456,118 \n1,578,220,209,981 \n1,200,532,713,975 \n[기타포괄손익누계액]\n5,011,173,208 \n4,512,733,369 \n3,024,273,130 \n[기타자본항목]\n(80,783,525,915)\n(20,774,292,442)\n23,311,375,844 \n자본총계\n2,641,580,736,619 \n2,426,373,960,581 \n2,072,890,161,113 \n종속ㆍ관계ㆍ공동기업투자주식의 평가방법\n원가법\n원가법\n원가법\n(2018.01.01~2018.12.31)\n(2017.01.01~2017.1.31)\n(2016.01.01~2016.1.31)\n매출액\n861,884,226,306 \n828,917,201,749 \n577,574,961,774 \n영업이익\n334,976,430,311 \n499,135,008,050 \n246,217,340,210 \n법인세비용차감전순이익\n312,274,618,195 \n489,959,261,511 \n261,444,895,791 \n당기순이익\n254,360,949,995 \n383,515,712,006 \n213,235,760,729 \n ㆍ기본주당이익\n2,040 \n3,079 \n1,715 \n']"
